Comparison
Abacavir Hypersensitivity C5768819 vs 2 Hydroxyglutaric Aciduria C2746066
Clinical comparison between Abacavir Hypersensitivity and 2 Hydroxyglutaric Aciduria for differential diagnosis and treatment planning.
Abacavir Hypersensitivity C5768819
A potentially serious immune reaction to the HIV drug abacavir. Genetic testing is required before starting treatment to identify those at risk of this reaction.
2 Hydroxyglutaric Aciduria C2746066
An organic acidemia where elevated acids accumulate in the body. It can cause neurological and developmental problems. Treatment focuses on supportive care and symptom management.
6 comparison axes
Onset
Abacavir Hypersensitivity C5768819
Variable
2 Hydroxyglutaric Aciduria C2746066
0-10
Onset patterns differ
Severity
Abacavir Hypersensitivity C5768819
severe
2 Hydroxyglutaric Aciduria C2746066
moderate
Different severity levels
Chronic
Abacavir Hypersensitivity C5768819
Acute
2 Hydroxyglutaric Aciduria C2746066
Chronic
Differing course
Communicable
Abacavir Hypersensitivity C5768819
No
2 Hydroxyglutaric Aciduria C2746066
No
Different transmission
Body System
Abacavir Hypersensitivity C5768819
immunologic
2 Hydroxyglutaric Aciduria C2746066
metabolic
Same/different system
Category
Abacavir Hypersensitivity C5768819
immunologic
2 Hydroxyglutaric Aciduria C2746066
metabolic
Different category
Bottom line
abacavir-hypersensitivity-C5768819 and 2-hydroxyglutaric-aciduria-C2746066 differ in severity, chronicity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | Abacavir Hypersensitivity C5768819 | 2 Hydroxyglutaric Aciduria C2746066 | Discriminating power |
|---|---|---|---|
| Timing of illness | Often begins after abacavir exposure; timing can vary. | Typically presents in childhood, reported range 0–10 years. | High |
| Dominant features | Multisystem immune symptoms may occur; exact pattern is not fixed. | Neurologic and developmental problems may occur. | Moderate |
| Course | Usually an acute reaction that can become severe. | Generally a chronic metabolic condition of moderate severity. | High |
When to favor each condition
Choose Abacavir Hypersensitivity C5768819 when
Symptoms arise during abacavir treatment
Drug exposure links the presentation to a possible hypersensitivity reaction.
High
HLA-related risk assessment is relevant
Genetic testing is required before starting abacavir to identify risk.
High
Acute immunologic illness is suspected
The supplied category is immunologic and severity is severe.
Moderate
Choose 2 Hydroxyglutaric Aciduria C2746066 when
Childhood neurologic or developmental concerns
The source describes neurologic and developmental problems.
Moderate
Organic acid accumulation is documented
Elevated organic acids support a metabolic acidemia rather than a drug reaction.
High
Chronic metabolic disease is being evaluated
The supplied course is chronic and the category is metabolic.
Moderate
How key tests differ
| Test | Abacavir Hypersensitivity C5768819 | 2 Hydroxyglutaric Aciduria C2746066 | Interpretation |
|---|---|---|---|
| Abacavir risk genetic testing | Required before treatment to identify people at risk. | Not indicated by the supplied description. | A risk result is not a diagnosis of hypersensitivity. |
| Organic acid testing | No characteristic abnormality is established here. | Elevated acids may be found. | An abnormal result needs clinician correlation with the clinical picture. |
| Clinical exposure history | Recent or ongoing abacavir exposure is central. | No drug trigger is described. | History helps separate an acute reaction from a chronic metabolic disorder. |
Prognosis comparison
Abacavir Hypersensitivity C5768819
- Outcome
- Can be serious; outcome depends on recognition and stopping the implicated drug under medical care.
- Factors
- Exposure history, severity, and timely clinical management.
2 Hydroxyglutaric Aciduria C2746066
- Outcome
- Often chronic, with neurologic or developmental effects possible; exact prognosis is not established here.
- Factors
- Age at onset, neurologic involvement, and response to supportive care.
Time frame: Acute for the drug reaction; childhood onset with a chronic course for the aciduria.
Neither condition is communicable. Individual prognosis requires clinician interpretation.
Complications comparison
| Complication | Presentation |
|---|---|
| Severe systemic reaction | Potentially serious and may worsen if exposure continues. Not the described complication pattern. Urgent clinician assessment is needed for suspected hypersensitivity. |
| Neurologic impairment | Not established as a defining feature. Neurologic problems may occur. Severity and permanence are not specified in the source. |
| Developmental difficulty | Not described. Developmental problems may occur. Supportive care and symptom management are the stated focus. |
Patient education highlights
- HighDo not restart abacavir independently
Suspected hypersensitivity requires prompt medical advice; re-exposure decisions belong to a clinician.
- HighGenetic testing before abacavir
Testing identifies risk but does not by itself confirm that a reaction has occurred.
- MediumMetabolic follow-up
2-hydroxyglutaric aciduria generally needs ongoing supportive and symptom-focused care.